Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
84 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014', provides an overview of the Deep Vein Thrombosis (DVT)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Deep Vein Thrombosis (DVT) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Deep Vein Thrombosis (DVT) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Deep Vein Thrombosis (DVT) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Deep Vein Thrombosis (DVT) Overview 7 Therapeutics Development 8 Pipeline Products for Deep Vein Thrombosis (DVT) - Overview 8 Pipeline Products for Deep Vein Thrombosis (DVT) - Comparative Analysis 9 Deep Vein Thrombosis (DVT) - Therapeutics under Development by Companies 10 Deep Vein Thrombosis (DVT) - Therapeutics under Investigation by Universities/Institutes 12 Deep Vein Thrombosis (DVT) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Deep Vein Thrombosis (DVT) - Products under Development by Companies 16 Deep Vein Thrombosis (DVT) - Products under Investigation by Universities/Institutes 17 Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development 18 Bristol-Myers Squibb Company 18 F. Hoffmann-La Roche Ltd. 19 Generex Biotechnology Corporation 20 Bayer AG 21 Merrion Pharmaceuticals Plc 22 Regado Biosciences, Inc. 23 Thrombotargets Corporation 24 Diakron Pharmaceuticals, Inc. 25 Armetheon, Inc. 26 Deep Vein Thrombosis (DVT) - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 apixaban - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 rivaroxaban - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 tecarfarin - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 TRX-1 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 DP-4088 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 REG-2 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Low Molecular Weight Heparin - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 TT-105 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 fondaparinux sodium - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 RNAi Oligonucleotide for DVT - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Small Molecules for Hematological Disorders and Cancer - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Deep Vein Thrombosis (DVT) - Recent Pipeline Updates 54 Deep Vein Thrombosis (DVT) - Dormant Projects 69 Deep Vein Thrombosis (DVT) - Discontinued Products 70 Deep Vein Thrombosis (DVT) - Product Development Milestones 71 Featured News & Press Releases 71 Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 71 Jul 15, 2014: Pradaxa (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism and Prevention of Recurrence 73 Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 73 Jun 26, 2014: Boehringer Ingelheim's Investigational Antidote for Pradaxa (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation 74 May 28, 2014: Boehringer Ingelheim Announces Comprehensive Settlement of U.S. Pradaxa (dabigatran etexilate mesylate) Litigation 75 May 22, 2014: Antidote for rapid reversal of Pradaxa progresses into next stage of clinical investigation with study in patients 76 May 15, 2014: As the benefits and safety of Pradaxa are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa to help more patients 76 Apr 25, 2014: Positive CHMP opinion for Pradaxa in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots 78 Mar 14, 2014: U.S. FDA Approves Eliquis (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 80 Feb 24, 2014: Thrombogenics' Board Announces Decision to Explore Strategic Options for the Company 81 Appendix 83 Methodology 83 Coverage 83 Secondary Research 83 Primary Research 83 Expert Panel Validation 83 Contact Us 84 Disclaimer 84
List of Tables Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2014 8 Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Deep Vein Thrombosis (DVT) - Pipeline by Bristol-Myers Squibb Company, H2 2014 18 Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 19 Deep Vein Thrombosis (DVT) - Pipeline by Generex Biotechnology Corporation, H2 2014 20 Deep Vein Thrombosis (DVT) - Pipeline by Bayer AG, H2 2014 21 Deep Vein Thrombosis (DVT) - Pipeline by Merrion Pharmaceuticals Plc, H2 2014 22 Deep Vein Thrombosis (DVT) - Pipeline by Regado Biosciences, Inc., H2 2014 23 Deep Vein Thrombosis (DVT) - Pipeline by Thrombotargets Corporation, H2 2014 24 Deep Vein Thrombosis (DVT) - Pipeline by Diakron Pharmaceuticals, Inc., H2 2014 25 Deep Vein Thrombosis (DVT) - Pipeline by Armetheon, Inc., H2 2014 26 Assessment by Monotherapy Products, H2 2014 27 Number of Products by Stage and Target, H2 2014 29 Number of Products by Stage and Mechanism of Action, H2 2014 31 Number of Products by Stage and Route of Administration, H2 2014 33 Number of Products by Stage and Molecule Type, H2 2014 35 Deep Vein Thrombosis (DVT) Therapeutics - Recent Pipeline Updates, H2 2014 54 Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2014 69 Deep Vein Thrombosis (DVT) - Discontinued Products, H2 2014 70
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
